Belmar Pharmacy

Belmar Pharmacy is a specialized pharmaceutical company focused on compounding medications, particularly hormone replacement therapies, tailored for individual patient needs across the United States. Founded in 1985 in Golden, US, Belmar Pharmacy provides compounding services with a specific emphasis on hormone health. The company has maintained its core focus on creating customized compounded medications for various hormonal conditions without any noted pivots in business strategy. CEO Rob Kilgore leads the company, which has executed two deals, with the most recent on March 16, 2021.

Belmar Pharma Solutions specializes in compounding pharmaceuticals with a particular focus on hormone health and wellness. The company's primary offerings include customized hormone replacement therapies (HRT) and a range of medications tailored to meet the unique needs of individual patients. These products are designed to address specific health issues, including those related to menopause, andropause, and other hormonal imbalances, ultimately aiming to improve patients' overall health and well-being. Belmar's client base primarily consists of healthcare providers and clinicians who seek reliable, patient-specific compounded medications for their practices.

The company serves a national market, providing its products and services across all 50 states, ensuring access to quality compounded medications for a diverse population of patients. Belmar Pharma Solutions generates revenue through direct transactions with healthcare providers who prescribe its compounded medications. The structure of these transactions is primarily B2B, where providers order customized formulations to meet the specific needs of their patients. Belmar’s flagship products include hormone pellets and other individualized hormone therapies, which are utilized in various clinical settings.

The company emphasizes quality and regulatory compliance in its offerings, which bolsters its reputation among practitioners. Revenue is derived from individual prescriptions as well as potential ongoing relationships with healthcare providers, who rely on Belmar's expertise for patient care. Pricing details for specific services or products are not disclosed, maintaining a professional standard in client interactions. Belmar Pharmacy plans to leverage the recent funding secured on March 16, 2021, from Capital Dynamics, which provided a senior secured second lien term loan to support an add-on acquisition.

The company is focused on expanding its offerings in compounded hormone therapies and is strategizing to enter new geographic markets within the U. S. These initiatives are expected to enhance their reach and service capabilities, although specific new product launches and market entry dates have not been disclosed.